Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pushen Penqiangyan is a Traditional Chinese Medicine (TCM) granule formulation developed by the Jilin Province Academy of Traditional Chinese Medicine for the treatment of chronic pelvic inflammatory disease (PID) and associated chronic pelvic pain. The drug is specifically designed to address the stagnation of heat and blood stasis syndrome, which is a common pathological classification in TCM for chronic pelvic inflammation. Its therapeutic mechanism involves clearing heat, detoxifying the body, and promoting blood circulation to resolve stasis in the pelvic cavity. Pushen Penqiangyan has been evaluated in Phase 2 clinical trials in China, focusing on its efficacy in reducing pelvic pain and improving clinical symptoms in women with chronic PID. It is typically administered orally as a granule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pushen Penqiangyan.